While PD-L1 expression detected by immunohistochemistry (IHC) is a required predictive biomarker in metastatic NSCLC for the selection of first-line PD-1 targeted monotherapy, the predictive role of PD-L1 in the neoadjuvant and adjuvant settings needs to be further defined. Here, CD274 is linked to non-small cell lung carcinoma.